



**LONDON  
STOCK  
EXCHANGE**

An LSEG Business

NS Miscellaneous



## UPDATE ON FUNDING

### [DIRECTA PLUS PLC](#)

Released 07:00:13 30 March 2026

RNS Number : 5969Y  
Directa Plus PLC  
30 March 2026

**The information communicated within this announcement is deemed to constitute inside information under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the Financial Markets (Miscellaneous Provisions) Act 2011 ("MAR"), and is disclosed in accordance with the Company's obligations under the Financial Services and Markets Act 2000 ("FSMA"). Upon the publication of this announcement, this inside information is now considered to be in the public domain.**

30 March 2026

### Directa Plus plc

("Directa Plus", the "Group" or the "Company")

### Update on Funding

Directa Plus (AIM: DCTA), a leading producer and supplier of graphene nanoplatelets based product for various industrial markets announces that it is in advanced discussions with an institutional investor for a £2.5m funding facility ("Proposed Facility") to extend the Company's cash runway. At this time there is no certainty that any funding transaction will be concluded.

Further to the notification of 27 February 2026, the Company has not been able to conclude discussions with Capital, LLC with regards to the terms of a non-dilutive potential loan (the "Potential Loan").

The Proposed Facility would be subject to shareholder approval and if no additional funding is secured, this will result in the Company and the Group not being a going concern and the Directors having to place the Company into administration.

As announced on 7 January 2026, the Group closed FY25 with gross cash balances of €1.5m (FY24 an effective cash runaway into early May 2026 and therefore needed to secure additional funding business, hence the discussions regarding the Potential Loan and the Proposed Facility.

The Board is continuing to progress both the potential sale of non-strategic land held by its Roma with an estimated value of at least €0.5m, as well as evaluating options for the business, including Board is continuing to implement the previously announced cost containment and cost reduction workforce reduction programme at Setcar. The Italian company, Directa Plus SpA continues its costs

Further information will be provided in due course.

This announcement has been approved by Giulio Cesareo, Chief Executive, on behalf of the Company

**For further information, please contact:**

**Directa Plus plc** +39 02  
Giulio Cesareo, CEO

**Singer Capital Markets (Nominated Adviser and Broker)** +44 20  
Rick Thompson / Phil Davies/Carl Diebitsch

**Alma Strategic Communications (Financial PR Adviser)** +44 20  
Justine James / Hannah Campbell / Rose Docherty directaplus@almastr

**About Directa Plus**

Directa Plus ([www.directa-plus.com](http://www.directa-plus.com)) is one of the largest producers and suppliers of graphene-based consumer and industrial markets. The Company's graphene manufacturing capability uses a proprietary process based on a plasma super expansion process. Starting from natural graphite, each step of Directa Plus expansion, exfoliation and drying - creates graphene-based materials and hybrid graphene materials uses and available in various forms such as powder, liquid and past.

This proprietary production process uses a physical process, rather than a chemical process, to produce graphene nanoplatelets, which enables Directa Plus to offer a sustainable, non-toxic products. Directa Plus's products are made of hybrid graphene materials and graphene nanoparticles (marketed as G+®) have multiple applications due to its properties. These G+® products can be families, with different products being suitable for specific practical applications.

Directa Plus was established in 2005 and is based in Lomaz (Como, Italy) and has been listed on the London Stock Exchange since May 2016. The Company holds the Green Economy Market Listing which recognises companies that contribute to the global green economy.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. [Terms and conditions](#), including restrictions on use and distribution apply.

---

© 2026 London Stock Exchange plc. All rights reserved.